Numab Therapeutics AG has raised CHF 100 million ($111.48 million) from a Series C financing round, enabling it to accelerate development of its lead antibody programme for multiple cancer indications. The latest financing was co-led by new investors Novo Holdings and HBM Partners. It comes a little over a year after Numab completed a Series B round for CHF 22 million.
